Identification of Potent Reverse Indazole Inhibitors for HPK1.
Journal
ACS medicinal chemistry letters
ISSN: 1948-5875
Titre abrégé: ACS Med Chem Lett
Pays: United States
ID NLM: 101521073
Informations de publication
Date de publication:
11 Mar 2021
11 Mar 2021
Historique:
received:
21
12
2020
accepted:
23
02
2021
entrez:
19
3
2021
pubmed:
20
3
2021
medline:
20
3
2021
Statut:
epublish
Résumé
Hematopoietic progenitor kinase (HPK1), a negative regulator of TCR-mediated T-cell activation, has been recognized as a novel antitumor immunotherapy target. Structural optimization of kinase inhibitor
Identifiants
pubmed: 33738073
doi: 10.1021/acsmedchemlett.0c00672
pmc: PMC7957946
doi:
Types de publication
Journal Article
Langues
eng
Pagination
459-466Informations de copyright
© 2021 American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
J Med Chem. 2010 Apr 8;53(7):2681-94
pubmed: 20000735
J Cell Biochem. 2005 May 1;95(1):34-44
pubmed: 15770651
Structure. 2019 Jan 2;27(1):125-133.e4
pubmed: 30503777
PLoS One. 2019 Mar 26;14(3):e0212670
pubmed: 30913212
Cancer Immunol Immunother. 2010 Mar;59(3):419-29
pubmed: 19787351
Elife. 2020 Sep 08;9:
pubmed: 32896273
Cancer Cell. 2020 Oct 12;38(4):551-566.e11
pubmed: 32860752
BMC Genomics. 2018 May 8;19(1):334
pubmed: 29739316
Blood. 2003 May 1;101(9):3687-9
pubmed: 12522005
Drug Metab Lett. 2009 Jan;3(1):28-34
pubmed: 19356114
J Med Chem. 2020 Nov 12;63(21):12156-12170
pubmed: 32633947
Immunol Res. 2012 Dec;54(1-3):262-5
pubmed: 22477524
SLAS Discov. 2021 Jan;26(1):88-99
pubmed: 32844715
Drug Metab Rev. 1999 Nov;31(4):817-99
pubmed: 10575553
ACS Med Chem Lett. 2018 Dec 18;10(2):153-160
pubmed: 30783496
J Biol Chem. 2001 Jun 1;276(22):18908-14
pubmed: 11279207
Nat Immunol. 2007 Jan;8(1):84-91
pubmed: 17115060
Cell Rep. 2018 Oct 2;25(1):80-94
pubmed: 30282040
Nat Rev Immunol. 2020 Nov;20(11):651-668
pubmed: 32433532